Kornimate/medical-research-clean huggingface dataset:
fluoxetine to reduce hospitalization from covid-19 infection (flor covid-19)

Conditions: Covid19

Summary: the current research is a pilot study to determine the feasibility of recruiting and retaining 40 participants diagnosed with covid-19. the purpose is to observe the early use of fluoxetine (commonly known as prozac) to reduce the severity of the covid-19 illness. fluoxetine is a drug that has been approved by the u.s. food and drug administration (fda) since 1987 for various mental health disorders.

morbidity and mortality resulting from covid-19 infections are associated with multisystem organ failure due to a rapid increase in cytokine production. fluoxetine has been shown to reduce the mechanisms that cause the cytokine storm that leads to covid-19 fatalities. this is a pilot study to assess feasibility of recruiting and retaining participants diagnosed with covid-19. the purpose of this study is to observe the early use of fluoxetine treatments on illness outcome: primary outcome is hospitalization and secondary outcomes of complications including intubation and death. additional secondary outcomes include effects on outcomes for depression and post-traumatic stress disorder, two common illnesses which may be improved by fluoxetine.

Eligibility criteria:
inclusion criteria: 1. english speaking participant 2. 18 years of age or older 3. able to give informed consent 4. tested positive for active sars-cov-2 infection and 1. it's been less than 10 days since symptoms first appeared; 2. fever persists for longer than 24 hours without the use of fever reducing medications; and 3. experiencing other symptoms of covid-19 as described by the cdc exclusion criteria: 1. prisoner or institutionalized patient 2. unable to give informed consent 3. less than 18 years of age 4. hospitalization 5. active bleeding requiring blood products in past week 6. diagnosed with bipolar disorder and not on mood stabilizing medication 7. known allergy or hypersensitivity to fluoxetine 8. currently taking a monoamine oxidase inhibitor (maoi) 9. currently taking an selective serotonin reuptake inhibitor (ssri) or selective norepinephrine reuptake inhibitor (snri) 10. outpatient and currently taking hydroxychloroquine 11. known pregnancy 12. breastfeeding 13. known prolonged qtc, such as congenital prolonged qtc syndromes

Keywords: covid-19 fluoxetine cytokine anti-inflammatory il-6
a study evaluating apg-115 as a single agent or in combination with apg-2575 in subjects with r/r t-pll and nhl

Conditions: T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma

Summary: the goal of this study is to evaluate the pharmacokinetics (pk), safety, and efficacy of apg-115 as a single agent or in combination with apg-2575 in patients with t-pll and nhl.

this is a phase iia, open-label, multi-center, clinical trial of interfering the binding of mdm2 oncoprotein with the tumor suppressor p53 protein, leads to increased p53 and p21 protein expression and activates p53-mediated apoptosis. the hypothesis is that apg-115 monotherapy and in combination with apg-2575 will shows good safety and efficacy in patients with r/r t-pll and nhl

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. patients with relapsed/refractory t-pll who have active disease and have received at least one prior therapy; patients with histologically confirmed diagnosis of nhl, nhl patients must be either relapsed, refractory, intolerant, or are considered ineligible for therapies known to provide clinical benefit; 3. patients must not have had chemotherapy or antibody therapy for 7 days prior to starting apg-115 and/or apg-2575. however, patients with rapidly proliferative disease may receive hydroxyurea or decadron until 24 hours prior to starting therapy on this protocol. 4. absolute neutrophil count (anc) ≥ 500/mm˄3; hemoglobin ≥ 60 g/l; platelet count ≥ 30,000/mm˄3 5. patients with adequate organ function; 6. eastern cooperative oncology group (ecog) performance status ≤ 2; 7. patient must have the ability to understand the requirements of the study and signed informed consent. a signed informed consent by the patient or his/her legally authorized representative is required prior to their enrollment on the protocol. exclusion criteria: 1. patient previously treated with a murine double minute 2 (mdm2) inhibitor. 2. known active, uncontrolled central nervous system (cns) malignancy 3. patients require graft versus host therapy, or require continued treatment with systemic immunosuppressive agents (calcineurin inhibitors within 4 weeks prior to the first dose of study drug). 4. patients who have any conditions or illness that, according to the opinions of the investigators or the medical monitor, would compromise patient safety or interfere with the evaluation of safety and efficacy to the study drug(s). 5. patients who have used strong cyp2c8 inhibitors, or moderate or strong cyp3a4 inhibitors or inducers within washout period of 14 days or 7 half-lives before the first administration of study drugs, whichever is longer.
comparison of peripheral and cerebral arterial flow in acute ischemic stroke: fimasartan vs. valsartan vs. atenolol

Conditions: Blood Pressure; Ischemic Stroke

Summary: confirm central blood pressure reduction effect of fimasartan, valsartan and atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.


Eligibility criteria:
inclusion criteria: * age ≥ 30 years old * acute ischemic stroke patient who has corresponding dwi(diffusion- weighted imaging) lesion correlated with symptom * after 7days, but within 28days from stroke onset * diagnosed with hypertension * hypertensive patients who taking anti-hypertensive drugs or sbp≥140mmhg * informed consent exclusion criteria: * patients with hemorrhagic stroke * patients with severe stroke - over nihss(national institutes of health stroke scale) 16 * uncontrolled hypertension (sbp ≥200mmhg) * patients with history of allergic reaction to any angiotensin ii antagonist * liver disease(more than double to normal level, sgot(serum glutamic-oxaloacetic transaminase ), sgpt(serum glutamic-pyruvic transaminase ), total bilirubin) * renal disease(serum creatinine ≥2.0mg/dl) * anemia(hb \< 8mg/dl) * thrombocytopenia( \< 10\^3/ml) * patients with secondary hypertension * childbearing and breast-feeding women * otherwise inappropriate patients depending on the investigator's decision
study of the outcomes of intraoperative margin assessment with marginprobe

Conditions: Breast Cancer

Summary: the combination of breast conserving surgery (lumpectomy) with radiation therapy has been shown to result in equivalent overall survival rates compared to mastectomy for the local treatment of breast cancer. as a result, the majority of patients diagnosed with breast cancer in the united states undergo lumpectomy as their primary surgical therapy. multiple studies have demonstrated the association between positive lumpectomy margins and an increased risk of ipsilateral breast tumor recurrence, even with postoperative radiation. studies report 20-40% of lumpectomy procedures result in one or more involved (positive) surgical margins, leading to the need for further surgery, emotional distress, poorer cosmesis, delay to adjuvant treatments, and increased cost. current available intraoperative margin assessment techniques include specimen xray, gross pathology, frozen section, and touch prep cytology. to reduce the incidence of positive margins, the marginprobe (dune medical devices, caesarea, israel) was developed to provide real-time, intraoperative assessment of the presence of tumor at the lumpectomy margin. in the current study, the investigators aim to determine the effectiveness of marginprobe as an adjunctive tool to standard practice for intraoperative identification of tumor at lumpectomy margins, and its ability to reduce positive margins and decrease the need for additional surgical procedures.

in the current study, the investigators aim to determine the effectiveness of marginprobe as an adjunctive tool to standard practice for intraoperative identification of tumor at lumpectomy margins, and its ability to reduce positive margins and decrease the need for additional surgical procedures. aims of the study: primary objectives 1. determine positive margin rate following lumpectomy secondary objectives 1. determine accuracy of intraoperative margin assessment with use of marginprobe plus standard of care (gross pathologic examination and/or intraoperative specimen xray) versus standard of care (gross pathologic examination and/or intraoperative specimen xray) alone. 2. determine impact of marginprobe on total tissue volume removed 3. determine the impact of marginprobe on the need for additional surgical procedures.

Eligibility criteria:
inclusion criteria: 1. subjects able to read and understand the informed consent exclusion criteria: 1. subjects unable to read or understand the informed consent.

Keywords: lumpectomy margins
assessment of navigation abilities in children with cerebral palsy and their peers

Conditions: Cerebral Palsy; Healthy Volunteers

Summary: spatial navigation skills are very important in everyday activities and quality of life but spatial navigation abilities are not part of the standard process of assessment and rehabilitation of patients. furthermore, it is known that children with cerebral palsy have impaired visuo-spatial competences. the main objective of this study is to evaluate and compare the spatial navigation abilities of typically developing children and of children with cerebral palsy using the "starmaze" application delivered by means of a head mounted display (hmd). the second aim is to investigate the user experience during the session. a similar application was already developed and tested in a virtual reality large scale platform whose size and cost limit the accessibility. therefore, the assessment (and future training) of navigation abilities with affordable and easy-to-use technology such as hmd open new perspectives.


Eligibility criteria:
inclusion criteria: * iq higher than 70 exclusion criteria: * subjects with epileptic issues * subjects with poor head control * visual acuity not correctable with eyeglasses
dose finding evaluation of kudzu root extract in women with menopause symptoms

Conditions: Menopause

Summary: the aim of the study is to investigate effects of daily intake of nordic kudzu for 28 days in 5 groups of 10 menopausal women with symptoms. groups:1) 3 capsules x3/day, 2) 3 capsules x2/day, 3) 2 capsules x3/day, 4) 2 capsules x2/day, 5) 3 capsules x1/day. each capsule equal 1.26 g kudzu root extract. outcome measures: serum and urine levels of biochemical marker of bone-degradation, ctx-i, and symptoms of menopause using the meopause rating scale (mrs).


Eligibility criteria:
inclusion criteria: 1. signed and dated informed consent 2. women in the age between 45 and 60 years considered late peri- (defined as having had a menstrual period more than 3 months ago but less than 12 months ago) or postmenopausal (defined as at least 12 consecutive months without any menstrual flow) at the time of screening 3. menopause symptoms, defined as a score of at least 5 in the menopausal rating scale (mrs) at screening 4. body mass index between 18 and 40 kg/m2 at the time of screening exclusion criteria: 1. allergy/hypersensitivity/intolerance to any components in the kudzu herbal extract powder capsules 2. past or present significant co-morbidity including, but not limited to: uncontrolled, severe renal, hepatic, cardiovascular, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease 3. history of breast cancer or other malignancy, except adequately treated basal cell or squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ 4. known history of clinically significant thromboembolism 5. current alcohol abuse 6. pregnancy, determined by positive serum human chorionic gonadotropin (hcg) test prior to randomization, except for women considered postmenopausal 7. breastfeeding women 8. participation in a study trial with any investigational new drug or food supplement within 3 months prior to the start of the study 9. clinically significant ecg abnormalities, as judged by the investigator 10. clinically significant biochemistry abnormalities including but not limited to alt or ast \>2.5 x uln or other clinically significant liver function parameters, as judged by the investigator 11. investigator considering the subject inappropriate for inclusion in the study based on medical interview and/or physical examination 12. use of local or systemic conventional hormone therapy regardless of indication or alternative medication including dietary supplements for the treatment of menopausal symptoms within 28 days prior to randomization.
implementation of nucleic acid amplification testing screening to identify acute and early hiv infection

Conditions: Acute HIV Infection

Summary: the investigators propose to study the impact of nucleic acid amplification testing (nat) screening for acute human immunodeficiency virus (hiv) and hepatitis c (hcv) infections and less-sensitive enzyme linked immunoassay (ls-eia) or 'detuned' testing vironostika, trinity biotech bed, or ortho-clinical diagnostic vistros eci for early hiv infection in conjunction with routine rapid hiv testing at hiv counseling and testing sites and venues in the san diego county. the overarching goal of this study is to develop and implement a system to identify, notify and engage into care those individuals with recent hiv infection in order to better define the hiv and hepatitis c virus (hcv) epidemics in the san diego county and to evaluate and characterize hiv transmission dynamics within the san diego population.


Eligibility criteria:
inclusion criteria: * persons presenting for hiv testing to public health department hiv testing site. * men and women \>13 years of age. * those who are 13 or older and younger than 18 should be an emancipated minor or have consent given by their legal representative. * participants 18 and over must be able to provide written consent. * participants should be available for follow up for a period of at least 2 weeks after enrollment exclusion criteria: * refusal to participate. * unable to provide informed consent.

Keywords: hiv acute infection primary infection seroconverters
effect of stress ball in angiography

Conditions: Pain, Acute

Summary: the target of this study was to determine the influence of stress ball application on pain and anxiety levels experienced by patients during angiography procedures.

the purpose of this research was to investigate the effect of stress ball application, which is a non-pharmacologic method, on the pain and anxiety levels of patients during the angiography procedure. the present randomized controlled trial was conducted on all adult patients undergoing angiography between january 2023 and june 2023 in the cardiovascular surgery clinic of a state hospital in eastern turkey. the sample population was composed of 120 randomized patients who underwent stress ball application and received routine care. numerical rating scale (nrs), patient information form, and state-trait anxiety inventory (stai) were employed for data collection. the mean nrs posttest score of the experimental group patients increased significantly less than the control group (p\<0.001), while the mean stai posttest score decreased significantly (p= 0.019). a positive significant correlation was determined between the mean nrs and stai post-test scores of the patients in the experimental group (p\<0.05). it was found that the level of state-trait anxiety decreased as the pain decreased. the stress ball applied during angiography decreased the anxiety and pain levels of the patients. stress ball application may be recommended as a complementary method to support pharmacologic treatment.

Eligibility criteria:
inclusion criteria: * no communication problems, * being older than 18 years of age, * having good mental health, * undergoing wrist angiography (radial angiography), * being willing to take part in the study. exclusion criteria: * any complication during angiography.

Keywords: pain angiography anxiety nursing stress ball
transcranial doppler on admission of patients with mild to moderate traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: patients with mild to moderate traumatic brain injury (tbi) are at risk for secondary neurological deterioration. their outcome within the first week after injury could be predicted by clinical signs, brain ct scan and transcranial doppler (tcd) on admission to the emergency room. the investigators aim to evaluate the diagnostic performance of tcd to screen patients presented with mild to moderate tbi and mild lesions on ct scan, i.e., trauma coma data bank, tcdb classification ii. the principal outcome measure is the negative predictive value of tcd.


Eligibility criteria:
criteria for inclusion: * 15 years of age or more * primary admission for mild tbi (gcs 14-15) or moderate (gcs 9-13) tbi. * with or without multiple injury. * with no hemodynamic or respiratory distress: sap \>90mmhg, spo2 \>92%,hemoglobin \> 8 g/dl. * with mild brain lesions on ctscan according to the traumatic coma data bank classification (tcdb) ii: diffuse injury with cisterns present and no midline shift, mixed density lesions \<25 ml. * transcranial doppler within 8 hours after the trauma. * patient affiliated to the social security system or equivalent criteria for exclusion: * severe tbi (gcs\<9) * penetrating tbi * patient with no brain ct scan * patient with normal brain ct scan (tcdb i), or severe brain ct scan (tcdb iii-iv) * hemodynamic or respiratory distress * patient treated with anticoagulants: oral anticoagulant, heparin, anti-platelet agent (except aspirin) * previous intracranial surgery * patient with sedation and mechanical ventilation * transcranial doppler unable * patient deprived of freedom by judicial or administrative decision * follow up at 7 days impossible * refusal consent to use data for statistics

Keywords: transcranial doppler mild and moderate traumatic brain injury neurological deterioration brain ct scan
a registry of laparoscopic bariatric surgery using stapling devices: observation of safety and clinical efficacy

Conditions: Obesity; Roux-en-Y Gastric Bypass; Gastrostomy; Nissen Sleeve

Summary: the purpose of this observational registry is to evaluate the safety and the clinical efficacy of laparoscopic bariatric surgery using stapling devices (easyendotm universal linear cutting stapler and reloads from ezisurg medical). the goal of the study will be achieved by reporting peri- and postoperative complications and the clinical outcome after surgery in a prospectively maintained database.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years of age at registry entry * patient and investigator signed and dated the informed consent form prior to the index-procedure. * patient has a bmi ≥ 35 kg/m2, with one or more related co-morbidities. * patient has a bmi ≥ 40 kg/m2. * patient is eligible for laparoscopic bariatric surgery. exclusion criteria: * patient is unable/unwilling to provide informed consent. * patient has a history of bariatric surgery. * patient is unable to comply with the registry protocol or the proposed follow-up visits. * patient has a contra-indication for laparoscopic bariatric surgery.
iti-007 for the treatment of agitation in patients with dementia, including alzheimer's disease

Conditions: Agitation in Dementia, Including Alzheimer's Disease

Summary: this is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of iti-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including alzheimer's disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of probable alzheimer's disease * clinically significant symptoms of agitation secondary to probable alzheimer's disease * able to attend outpatient clinic visits with primary caregiver exclusion criteria: * unable to comply with study procedures * considered medically inappropriate for study participation
pilot observational study examining the effect of endocrine therapy on aging

Conditions: Breast Neoplasm Female; Arthralgia; Aging

Summary: the goal of this pilot observational study is to learn about the feasibility of collecting patient-reported data and stool and blood samples from patients age 65 and older treated with aromatase inhibitor therapy for breast cancer. participants will be treated with standard of care aromatase inhibitor therapy and will undergo serial phlebotomy, complete patient-reported questionnaires, and submit serial stool samples. the main exploratory translational questions it aims to obtain preliminary data for are: * what are the effects of aromatase inhibitor therapy on biomarkers of aging? * what are the effects of aromatase inhibitor therapy on the microbiome? these data will be used for the development of future definitive studies.


Eligibility criteria:
inclusion criteria * female gender. * cohort 1: age 65 or greater. cohort 2: age younger than 65 years * cohort 1 participants (starting ai therapy): histologically proven stage 0-iii carcinoma of the breast or at high risk for development of breast cancer who are planning to undergo treatment with neoadjuvant or adjuvant aromatase inhibitor therapy (anastrozole, letrozole, or exemestane). * cohort 1 controls (no endocrine therapy): histologically proven stage 0-iii carcinoma of the breast or high risk for development of breast cancer and who are not planning to undergo treatment with any endocrine therapy (ai or tamoxifen). * participants cohort 2 (starting ai therapy): histologically proven stage 0-iii carcinoma of the breast or at high risk for development of breast cancer who are planning to undergo treatment with neoadjuvant or adjuvant aromatase inhibitor therapy (anastrozole, letrozole, or exemestane). * concurrent treatment with gnrha therapy, radiation therapy, cdk4/6 inhibitor, bisphosphonate, parp inhibitor, and/or anti-her2 therapy is permitted. prior tamoxifen is permitted. * the patient is aware of the nature of her diagnosis, understands the study requirements, risks, and discomforts, and is able and willing to sign an informed consent form. * able to read and understand english. exclusion criteria * distant metastatic disease * prior aromatase inhibitor therapy except in the context of fertility treatment. * use of exogenous estrogen supplementation other than vaginal estrogen preparations.

Keywords: aromatase inhibitor microbiome
to evaluate the efficacy and safety of jw0201 added on in patients with t2dm

Conditions: Type 2 Diabetes Mellitus

Summary: a multicenter, randomized, double blind, placebo controlled, parallel, phase ⅲ study to evaluate the efficacy and safety of jw0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with c2202 and c2204

a multicenter, randomized, double blind, placebo controlled, parallel, phase ⅲ study

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * type 1 diabetes mellitus * the subject not meet the specified hba1c and fpg

Keywords: diabetes mellitus